Search

Asabys launches a fund of up to €120M to transform scientific discoveries into innovative healthcare companies, reinforcing its commitment to technology transfer and the creation of deep tech

Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off.

Partnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo lentiviral vectors for the advanced therapies sector.

Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve vector quality, and low batch variability.

We welcome the Biotech Act I, but believe its ambition and level of specificity must be strengthened to ensure a real impact on funding, industrial scale-up, and biotechnology innovation in Europe; a

Rubén Pérez-Mañanes is an orthopaedic oncology surgeon at the HGUGM (Gregorio Marañón University General Hospital), deputy director of the Gregorio Marañón Health Research Institute and an ANECA

Meet StablePharma, our new member. We spoke with Lorena Carmona Rodríguez, Lab Manager/Senior Scientist.

In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12

These results come from a preclinical study conducted by the Cell Engineering team at Integra Therapeutics using the FiCAT gene-writing platform.

Meet AllBiotech, our new member. We spoke with Pablo Goñi, CEO.

The company presented its new Branded Ingredient at Vitafoods Europe, the nutraceutical industry trade show, which took place this week in Barcelona